Refractive surgery

SightMD Welcomes The Ophthalmic Center To Its Expert Team

Retrieved on: 
화요일, 3월 28, 2023
Doctor of Medicine, Molecular biology, Contact, Glaucoma, Vincent, Harry S. Truman Memorial Veterans' Hospital, American Optometric Association, Miller Place, New York, Partnership, Refractive surgery, Macular degeneration, Education, S4, Doctor of Philosophy, Life, OD, Refraction, Cataract, University School, Bachelor of Arts, Optometry, Ophthalmology, Quality of life, Ward Melville High School, New York Medical College, University of St Andrews, Eye, Research, Washington University in St. Louis, Three Villages, Patient, New York University Grossman School of Medicine, United Kingdom, Hofstra University, IOL, Captain James A. Lovell Federal Health Care Center, Nursing, LASIK, New York University, MD

HAUPPAUGE, N.Y., March 28, 2023 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform, today announced a strategic partnership with The Ophthalmic Center (TOC Eye), an eastern Long Island based ophthalmology practice. Through this strategic partnership the practices in East Setauket, 8 Technology Drive East Setauket, NY 11733 and in Wading River, 6144 Route 25A Wading River, NY 11792 will expand SightMD's presence by adding two location and four providers, growing SightMD's current footprint to 40+ locations and 85+ providers across New York.

Key Points: 
  • HAUPPAUGE, N.Y., March 28, 2023 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform, today announced a strategic partnership with The Ophthalmic Center (TOC Eye), an eastern Long Island based ophthalmology practice.
  • Thousands of people have trusted their award-winning team with their families' eye care and vision correction treatment, and we are grateful for the opportunity to have them join the expert team at SightMD.
  • The doctors at TOC Eye joining the SightMD team are Vincent P. Basilice, MD, Michael Conners, MD, Alexander Llinas, MD, and Alex Schaffer, OD.
  • Jeffrey Martin, MD, Co-founder and President of SightMD, said, "I am honored to be partnering with the eye doctors of The Ophthalmic Center.

Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

Retrieved on: 
목요일, 3월 16, 2023
Society, DME, Health, Therapy, Annual general meeting, Eye, Refractive surgery, Cerebral edema, Patient, Minimisation, Bangladesh Technical Education Board, Inflammation, Dexamethasone, Cataract, Diabetic retinopathy, NIH, OCS, Retina, American Society of Cataract and Refractive Surgery, CME, Confusion, Safety, ASCRS, Clinical Therapeutics, Dentistry, Pharmaceutical industry, Orbicularis oculi muscle, Pain

Completed enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to approval.

Key Points: 
  • Completed enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to approval.
  • The OPTIMIZE (Once-daily Post ocular surgery Treatment for InflaMmation and paIn to minimiZE drops) trial is a randomized, double-blind, placebo-controlled Phase 3 trial in 25 participating sites across the US, with 240 patients.
  • The once-a-day data from the trial demonstrated that OCS-01’s unique formulation may allow for effective and safe once a day dosing.
  • Riad Sherif MD, CEO of Oculis, said: “Oculis has taken a material step forward in advancing OCS-01’s Phase 3 clinical trial and I wish to congratulate everyone involved.

Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%

Retrieved on: 
월요일, 3월 13, 2023
Biotechnology, Pharmaceutical, Optical, Health, Society, Cataract, Ambulatory Surgery Center Association, Outpatient surgery, Centers for Medicare & Medicaid Services, CMS, ASC, Medicare, Refractive surgery, ASCRS, Intravitreal injection, ASP, Optometry, American Society of Cataract and Refractive Surgery, China Biologic Products, Eye, WAC, Ophthalmology, Health insurance

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3%, which is indicated for ocular surface anesthesia.

Key Points: 
  • Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3%, which is indicated for ocular surface anesthesia.
  • CMS grants pass-through status to certain new and innovative medical devices, drugs, and biological products.
  • Drugs that are administered in the ASC and HOPD settings can have pass‑through status and be reimbursed accordingly by Medicare.
  • “We are grateful to CMS for their approval of transitional pass-through reimbursement status for IHEEZO and for their support of our mission to make innovative ophthalmic prescription medications accessible and affordable,” said Mark L. Baum, Chairman and Chief Executive Officer of Harrow.

Leiters and EyeConnect International Announce Continued Corporate Partnership

Retrieved on: 
수요일, 2월 1, 2023
FDA, ASCRS, Senior, Health, ECI, Cataract, Refractive surgery, Ophthalmology, American Society of Cataract and Refractive Surgery, Michael Leiter, Patient, Partnership, Pharmaceutical industry, Nursing

DENVER, Feb. 1, 2023 /PRNewswire/ -- Leiters, a trusted FDA-registered 503B outsourcing provider of compounded sterile preparations and pharmacy services, announced today that it has renewed its corporate partnership with EyeConnect International (ECI) in support of their digital ophthalmic clinical knowledge-sharing platform for ophthalmologists world-wide.

Key Points: 
  • DENVER, Feb. 1, 2023 /PRNewswire/ -- Leiters, a trusted FDA-registered 503B outsourcing provider of compounded sterile preparations and pharmacy services, announced today that it has renewed its corporate partnership with EyeConnect International (ECI) in support of their digital ophthalmic clinical knowledge-sharing platform for ophthalmologists world-wide.
  • "We are honored that Leiters recognizes the value of peer-to-peer education," said David Karcher, Board Member, EyeConnect International and former Executive Director, American Society of Cataract and Refractive Surgery (ASCRS).
  • "Partnering with EyeConnect International extends our commitment to ophthalmologists, health care systems, and their patients," said Timothy Askew, Senior Vice President and General Manager for Leiters.
  • "We are delighted to announce this partnership and look forward to collaborating with EyeConnect International on new and innovative ways to extend the reach of their global knowledge-sharing platform."

Actress and Beauty Entrepreneur Peyton List Sets Her Sights on 2023 with Upgraded Vision from Life-Changing EVO ICL Lenses

Retrieved on: 
수요일, 1월 11, 2023
Medical Devices, Surgery, Women, Entertainment, Men, Celebrity, General Health, Consumer, Health, Optical, Netflix, American Society of Cataract and Refractive Surgery, Lens (anatomy), ASCRS, Literature, Quality, Learning, Ophthalmology, Nave, Glasses, FDA, Myopia, Partnership, EVO, Prevalence, Night vision, Paramount+, Lens, Dry eye syndrome, Iris, Astigmatism, School Spirits, Society, Refractive surgery, Multimedia, Eye, Cataract, Intraocular lens, Medical device, Telescopic sight, LASIK, Patient, Life

EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia with or without astigmatism.

Key Points: 
  • EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia with or without astigmatism.
  • View the full release here: https://www.businesswire.com/news/home/20230111005302/en/
    Peyton List, actress and entrepreneur, sets her sights on a new acting role without the hassles of eyeglasses and contact lenses thanks to her new EVO ICL lenses - a life-changing vision correction lens designed for the correction/reduction of myopia (nearsightedness) and astigmatism.
  • Recently, List had EVO lenses implanted by her doctor to upgrade her vision.
  • List went from struggling with the hassles of contact lenses, both on and off the film set, to having clear 20/20 vision following the EVO procedure.

Woolfson Eye Institute Opening an Office in Marietta, Georgia

Retrieved on: 
토요일, 11월 19, 2022
Indian Medical Association, American Society of Cataract and Refractive Surgery, Dyak, American Academy of Ophthalmology, American Medical Association, DO, WEI, Society, Retina, DRS, Permit, Macular degeneration, Intraocular lens, Glaucoma, Contact lens, OD, Sprayberry High School, Diabetic retinopathy, Patient, ICL, Wells Fargo, Outpatient surgery, Cataract, Keratoconus, Eyelid, Surgeon, American Academy, International Society, Refractive surgery, Hospital, Veterinary medicine, MD, LASIK, Ophthalmology

MARIETTA, Ga., Nov. 19, 2022 /PRNewswire/ -- Woolfson Eye Institute will open a new Marietta office in November 2022.

Key Points: 
  • MARIETTA, Ga., Nov. 19, 2022 /PRNewswire/ -- Woolfson Eye Institute will open a new Marietta office in November 2022.
  • The practice ultimately evolved into a referral destination for patients in need of other types of eye care, as well.
  • About LASIK eye surgery and Jonathan Woolfson, MD
    Jonathan Woolfson, MD, a LASIK pioneer, and his team of surgeons have performed over 100,000 LASIK procedures.
  • Woolfson Eye Institute, headquartered in Atlanta, GA, is the Southeast's leading provider for LASIK, oculoplastics, cataract surgery, retina, glaucoma and other eye disorders.

ViaLase Strengthens Executive Team with the Appointments of Tom Frinzi as Executive Chairman of the Board, Richard Lewis, M.D., as Chief Medical Officer, and Shawn O'Neil as Chief Commercial Officer

Retrieved on: 
화요일, 11월 15, 2022
Health, Federal Food, Drug, and Cosmetic Act, Laser, Technology, American Society of Cataract and Refractive Surgery, Board, Goal, Compliance, Leadership, OCT, Organization, American Glaucoma Society, Trabecular meshwork, FDA, Sacramento, California, Industry, Society, Alcon, Glaucoma, Patient, CEO, Cataract, Aerie Pharmaceuticals, Flight, CE marking, Johnson & Johnson Vision, Treatment, CA, Refractive surgery, Management, Risk management, 3D printing, Medical device, LASIK, Lean

ALISO VIEJO, Calif., Nov. 15, 2022 /PRNewswire/ -- ViaLase, Inc. today announced the appointments of Tom Frinzi as Executive Chairman of the Board, Richard Lewis, M.D., as Chief Medical Officer, Shawn O'Neil as Chief Commercial Officer, and Brendan O'Herlihy as Vice President, Global Commercial Operations. The executives will play key roles at ViaLase as the company develops its novel, non-invasive, femtosecond laser with integrated OCT imaging that is accurate to the micron level. This OCT-guided femtosecond laser technology is designed to perform the first femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) procedure for the treatment of primary open-angle glaucoma (POAG).

Key Points: 
  • This OCT-guided femtosecond laser technology is designed to perform the first femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) procedure for the treatment of primary open-angle glaucoma (POAG).
  • This puts ViaLase in a position of strength as we prepare for CE Mark and FDA 510k clearance.
  • It's an exciting time in the evolution of the company, and I'm proud to be a part of this journey."
  • Mr. O'Herlihy has 30 years of leadership and management experience in medical device manufacturing; clinical development; and technical, operational, and commercial support.

Medicare cuts harming seniors' access to surgical care set to take effect in less than two months

Retrieved on: 
화요일, 11월 1, 2022
Surgeon, FACS, Neurology, American Academy of Ophthalmology, Congress, FASA, Breast cancer, MBA, Politics, Refractive surgery, Centers for Medicare & Medicaid Services, Advocacy, American Society of Cataract and Refractive Surgery, Patient, Ophthalmology, Risk, Physician, CMS, American Society of Anesthesiologists, Statute, American Society of Breast Surgeons, Medicare, Anesthesiology, Woman, Investor, Cataract, Health policy, Multimedia, ACS, Society for Vascular Surgery, Quality of life, Center, Society, Association, Global Initiative for Emergency and Essential Surgical Care, Solution, Pharmaceutical industry, Health insurance, MD

WASHINGTON, Nov. 1, 2022 /PRNewswire/ -- The 2023 Medicare Physician Fee Schedule final rule released today by the Centers for Medicare & Medicaid Services (CMS) confirms the nearly 4.5 percent cut to surgeons and anesthesiologists, harming patient access to needed surgical care, the Surgical Care Coalition said today. 

Key Points: 
  • "Without Congressional action, vulnerable seniors' nationwide access to timely, high quality, and essential surgical care will be negatively impacted.
  • Combined with a 4% Medicare cut stemming from the Statutory Pay-As-You-Go Act, surgical care will face a nearly 8.5% Medicare cut on January 1, 2023.
  • Meanwhile, significant medical inflation, along with staffing and supply chain shortages, continues to harm surgical care teams across the country.
  • The Surgical Care Coalition advocates for access to quality surgical care for all Americans.

Woolfson Eye Institute Announces New Location in Snellville, Georgia

Retrieved on: 
목요일, 10월 27, 2022
Cataract, Patient, Indian Medical Association, Glaucoma, Refractive surgery, Cornea, American Academy, Surgeon, WEI, Outpatient surgery, Philosophy, Permit, American Academy of Ophthalmology, International Society, Keratoconus, Society, Pterygium, DRS, American Society of Cataract and Refractive Surgery, DO, American Medical Association, Blepharoplasty, Hospital, Medicine, Veterinary medicine, LASIK, MD, Ophthalmology, Retina

About LASIK eye surgery and Jonathan Woolfson, MD

Key Points: 
  • About LASIK eye surgery and Jonathan Woolfson, MD
    Jonathan Woolfson, MD, a LASIK pioneer, and his team of surgeons have performed well over 100,000 LASIK procedures.
  • In fact, over 300 eye doctors have entrusted Dr. Woolfson with their own LASIK surgery.
  • Woolfson Eye Institute, headquartered in Atlanta, GA, is the Southeast's leading provider for LASIK, oculoplastics, cataract surgery, retina, glaucoma and other eye disorders.
  • WEI has state-of-the-art LASIK surgery centers in Georgia, North Carolina, and Tennessee along with a fully accredited Ambulatory Surgery Center in Atlanta (Permit #: 060-414).

Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams

Retrieved on: 
월요일, 10월 17, 2022
U.S. Securities and Exchange Commission, Time, Refractive surgery, Therapy, Water-dropper (calligraphy), Myopia, Regulation of tobacco by the U.S. Food and Drug Administration, Society, Patient, Naitō, Eye, Technology, Food, Marketing, Severe cognitive impairment, Cataract, CEO, American Society of Cataract and Refractive Surgery, Adult, GLOBE, Presbyopia, Forward-looking statement, Mydriasis, COVID-19, Compliance, Pharmaceutical industry, Dietary supplement, Matsui

The investigational Optejet dispenser administers ophthalmic solutions horizontally using the company's proprietary Microdose Array Print (MAP) technology.

Key Points: 
  • The investigational Optejet dispenser administers ophthalmic solutions horizontally using the company's proprietary Microdose Array Print (MAP) technology.
  • The Optejet dispenser is designed to administer 1/5 the volume of solution compared to a traditional eyedropper, making doses less likely to spill or run onto the patient's face.
  • "Traditional eye drops typically overdose a patient's eye with medication and preservatives, which can lead to significant dose-related side effects," said Michael Rowe, CEO of Eyenovia.
  • It found that nearly 90% of children using the Optejet once-daily treatment successfully complied with their treatment regimen.